Scholarlink

Purpose <p>The Surpass Elite (Stryker Neurovascular) is the latest generation of the Surpass flow diverter (FD) platform, featuring a higher braid angle consistently exceeding 150°, the BioStealth surface modification, and an expanded size matrix. We report our early single-center experience with the Surpass Elite in the treatment of intracranial aneurysms.</p> Methods <p>Retrospective analysis of a prospectively maintained database including 21 consecutive patients with 22 intracranial aneurysms treated with the Surpass Elite between March 2025 and January 2026 at a single high-volume neurointerventional center. We recorded and analyzed device deployment characteristics and imaging and clinical follow-up, as well as intraprocedural, early (&lt; 30 days), and delayed (&gt; 30 days) neurological complications.</p> Results <p>Twenty-one patients (16 women, mean age 47 years) were treated for 22 aneurysms (3 previously ruptured, all saccular). Twenty-four devices were successfully deployed (mean of 1.1 devices per patient), with a 100% technical success rate. Five procedures (23.8%) were performed via radial access. No intraprocedural, early, or delayed neurological complications were observed. No intracranial hemorrhage or mortality occurred. All patients maintained a modified Rankin Scale score of 0 throughout follow-up. Imaging follow-up, available in 19/22 (86.4%) aneurysms (median 5 months), demonstrated complete occlusion (OKM grade D) in 12/19 (63.2%) and adequate occlusion (OKM grades C-D) &lt; in 16/19 (84.2%).</p> Conclusion <p>Within the limits of a small single-center cohort and short imaging follow-up, our early experience with the Surpass Elite suggests favorable technical performance, an encouraging safety profile, and early occlusion rates consistent with previously reported flow diverters. Larger multicenter prospective studies with imaging follow-up extended to 12–24 months are warranted to confirm these preliminary findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early experience with the Surpass Elite flow diverter for unruptured intracranial aneurysms

  • 期刊论文

  • 发表日期：

    2026年6月2日

查看全文
  • Mohamed Ajem,
  • Erwah Kalsoum,
  • Firas Farhat,
  • Titien Tuilier,
  • Maxime Geismar,
  • Luca Scarcia

摘要

Purpose

The Surpass Elite (Stryker Neurovascular) is the latest generation of the Surpass flow diverter (FD) platform, featuring a higher braid angle consistently exceeding 150°, the BioStealth surface modification, and an expanded size matrix. We report our early single-center experience with the Surpass Elite in the treatment of intracranial aneurysms.

Methods

Retrospective analysis of a prospectively maintained database including 21 consecutive patients with 22 intracranial aneurysms treated with the Surpass Elite between March 2025 and January 2026 at a single high-volume neurointerventional center. We recorded and analyzed device deployment characteristics and imaging and clinical follow-up, as well as intraprocedural, early (< 30 days), and delayed (> 30 days) neurological complications.

Results

Twenty-one patients (16 women, mean age 47 years) were treated for 22 aneurysms (3 previously ruptured, all saccular). Twenty-four devices were successfully deployed (mean of 1.1 devices per patient), with a 100% technical success rate. Five procedures (23.8%) were performed via radial access. No intraprocedural, early, or delayed neurological complications were observed. No intracranial hemorrhage or mortality occurred. All patients maintained a modified Rankin Scale score of 0 throughout follow-up. Imaging follow-up, available in 19/22 (86.4%) aneurysms (median 5 months), demonstrated complete occlusion (OKM grade D) in 12/19 (63.2%) and adequate occlusion (OKM grades C-D) < in 16/19 (84.2%).

Conclusion

Within the limits of a small single-center cohort and short imaging follow-up, our early experience with the Surpass Elite suggests favorable technical performance, an encouraging safety profile, and early occlusion rates consistent with previously reported flow diverters. Larger multicenter prospective studies with imaging follow-up extended to 12–24 months are warranted to confirm these preliminary findings.